Shares of pharmaceutical agency Wanbury Ltd have been buying and selling 4% decrease on Tuesday, 20 Could, regardless of securing good manufacturing practices (GMP) certification from Brazil’s Nationwide Well being Surveillance Company (ANVISA) for its facility in Raigad, Maharashtra.
The accreditation confirms that the corporate follows Brazilian GMP standards, that are in step with the World Well being Organisation’s suggestions, in response to an alternate submitting.
The accreditation primarily addresses the manufacturing of metformin hydrochloride, an energetic pharmaceutical ingredient (API) used to deal with diabetic mellitus.
Wanbury’s authorised plant is situated at A-15, MIDC Industrial Space, Patalganga, Raigad District, Maharashtra. The accreditation is legitimate till 12 Could, 2027, with a caveat noting that it could be revoked if the corporate fails to satisfy present GMP standards.
On 12 Could, Wanbury introduced that the corporate had obtained clearance and certification from ANVISA, Brazil, for its Tanuku location in Andhra Pradesh as effectively.
In September 2024, the European Directorate for the High quality of Medicines (EDQM) gave the corporate a certificates of appropriateness (CEP) for its energetic pharmaceutical ingredient (API), Dextromethorphan. This API is usually used as an antitussive and is a vital part in cough suppressant medicines.
Wanbury Ltd earned Rs 173.84 crore in Q4FY25, up from Rs 140.33 crore the earlier 12 months. The corporate made a web revenue of Rs 20.25 crore in This fall FY25, down from Rs 33.63 crore in the identical interval the earlier 12 months.
At 12 pm, Wanbury shares have been buying and selling at Rs 292.62, down 3.82%.
Keep Forward with Wanbury Ltd. Ask the Analyst.
Prepared to speculate like a professional? Unicorn Indicators app equips you with 100+ Free instruments and information it’s essential succeed. Obtain the Unicorn Indicators app and achieve entry to day by day inventory lists and insightful market evaluation and way more!
